news
Ozanimod successful in clinical trials for multiple sclerosis
The findings from the two pivotal phase 3 trials pave the way for ozanimod to enter the New Drug Approval process with the FDA...
List view / Grid view
Multiple sclerosis
news
NHS England partners with Merck allowing people with MS immediate access to cladribine
NHS England has announced a commercial agreement that allows patients in England immediate access to the innovative new multiple sclerosis treatment...
news
BIOCAD does its sums for growth
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market
news
Novartis real-world data confirms benefit of Gilenya in relapsing MS
28 April 2017 | By Niamh Marriott, Junior Editor
Novartis announced data from the MS-MRIUS study, which confirmed the effectiveness of Gilenya (fingolimod) in the real-world setting...
news
Apitope’s Phase II multiple sclerosis trial a success
22 February 2017 | By Niamh Marriott, Digital Editor
Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase IIa, open-label, one arm study evaluated the effects of…
news
Researchers discover severe side effects of approved multiple sclerosis medication
20 January 2017 | By Niamh Marriott, Digital Editor
The multiple sclerosis therapy alemtuzumab can trigger severe, unpredictable side effects...
news
Apitope regains global rights to its multiple sclerosis treatment from Merck
18 October 2016 | By Niamh Louise Marriott, Digital Content Producer
In 2009, Apitope granted exclusive worldwide rights to Merck to develop and commercialise ATX-MS-1467 but now have successfully regained...
news
Novartis’ long term RRMS drug limits disease progression
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Gilenya impacts four key measures of disease activity: relapses, MRI lesions, brain shrinkage (brain volume loss) and disability progression...
news
RedHill Biopharma receives patent approval for MS drug
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
A first Phase III study with RHB-104 for the treatment of Crohn’s disease is currently ongoing, as well as a Phase IIa proof-of-concept study for the treatment of MS...
news
Novartis’ phase III MS study successfully meets endpoints
25 August 2016 | By Novartis
The study included 1,651 people with SPMS randomised to receive either 2mg BAF312 or placebo in a 2:1 ratio respectively, the primary endpoint being an improvement in the time to three-month confirmed disability progression, as measured by the expanded disability status scale (EDSS), versus placebo...
news
Last patient visit in Phase IIa study with RHB-104 for multiple sclerosis
3 August 2016 | By RedHill Biopharma Ltd.
The last patient visit has been completed in the Phase IIa study evaluating RHB-104 in patients treated for relapsing-remitting multiple sclerosis (RRMS)...
news
RedHill Biopharma has positive results with RHB-104 for multiple sclerosis
1 August 2016 | By RedHill Biopharma Ltd.
RHB-104 for relapsing-remitting multiple sclerosis show positive safety and efficacy signals after the 24-week treatment period ...
news
EC grants marketing authorisation for Zinbryta in multiple sclerosis
5 July 2016 | By Victoria White, Digital Content Producer
The approval of Zinbryta is supported by results from two studies, including DECIDE, the largest and longest head-to-head Phase III study ever conducted in MS...
news
Ocrevus marketing applications under review by the EMA and FDA
28 June 2016 | By Victoria White, Digital Content Producer
If approved by the EMA and FDA for both indications, Ocrevus would be the first and only treatment for both forms of multiple sclerosis...
news
Replacing diseased immune system halts MS progression
10 June 2016 | By Victoria White, Digital Content Producer
A study shows that completely wiping out the immune system and then regenerating a new one can eliminate all signs of damaging brain inflammation in MS...
